Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-10-08 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocr
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Orano Med announcing positive clinical trial results for their investigational drug AlphaMedix. It details efficacy endpoints, safety profiles, and future regulatory plans. It does not constitute a formal financial report, earnings call transcript, or regulatory filing, but rather a corporate announcement regarding research and development progress. Under the provided categories, this fits best as a general regulatory announcement or corporate press release, which falls under the 'RNS' (Regulatory Filings) category as the fallback for miscellaneous corporate announcements.
2025-10-08 English
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement signifi
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Orano Med announcing positive Phase 2 clinical trial results for their drug candidate, AlphaMedix. It details the trial methodology, efficacy outcomes, and future regulatory steps. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains substantive clinical data and analysis. It is best classified as a general regulatory/corporate announcement under the RNS category.
2025-10-08 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (September 29, 2025, to October 3, 2025). It includes detailed tables of daily aggregated volumes and individual transaction records, which is the standard format for 'Transaction in Own Shares' filings under market abuse regulations (MAR).
2025-10-06 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding its share repurchase program, detailing daily aggregated volumes and individual transaction records (date, time, price, quantity, and market). This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of companies buying back their own shares.
2025-10-06 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure titled 'Déclaration des transactions sur actions propres' (Declaration of transactions in own shares) for Sanofi. It provides a detailed breakdown of share buyback transactions conducted between September 22, 2025, and September 26, 2025, including daily aggregated data and a transaction-by-transaction log. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-09-29 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (September 22-26, 2025). It includes detailed tables of daily volumes, weighted average prices, and individual transaction logs, which is characteristic of a 'Transaction in Own Shares' filing. This aligns perfectly with the definition for the POS category.
2025-09-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.